PharmaEssentia Announces Board Approval of 2026 Second Quarter Consolidated Financial Report

1. Date reported to or resolved by the Board of Directors: 115/08/10 2. Audit Committee approval date: 115/08/10 3. Reporting period for financial statements or self-prepared annual financial information: Start date to end date (YYY/MM/DD ~ YYY/MM/DD): 115/01/01 ~ 115/06/30 4. Cumulative operating revenue from January 1 to the end of this period (in thousands of NT$): 11,976,809 5. Cumulative operating gross profit (loss) from January 1 to the end of this period (in thousands of NT$): 10,960,074 6. Cumulative operating income (loss) from January 1 to the end of this period (in thousands of NT$): 5,242,490 7. Cumulative pre-tax net profit (loss) from January 1 to the end of this period (in thousands of NT$): 5,534,183 8. Cumulative net profit (loss) for the period from January 1 to the end of this period (in thousands of NT$): 4,679,591 9. Cumulative net profit (loss) attributable to owners of the parent from January 1 to the end of this period (in thousands of NT$): 4,679,591 10. Cumulative basic earnings per share (loss) from January 1 to the end of this period (in NT$): 11.35 11. Total assets at the end of the period (in thousands of NT$): 44,110,958 12. Total liabilities at the end of the period (in thousands of NT$): 7,294,881 13. Equity attributable to owners of the parent at the end of the period (in thousands of NT$): 36,816,077 14. Other matters to be disclosed: In accordance with IAS 33, the basic earnings per share for the second quarter and first half of 2026 have been retrospectively adjusted based on the number of shares after capitalization.